Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652
Construction of a variable fragment (Fv)-immunoglobulin A (IgA) anti-receptor binding domain (RBD) SARS-CoV-2 library based on IgA from Indonesian COVID-19 survivors., PMID:40403817
The Combination of TLR4 and TLR9 Agonists with Self-Amplifying RNA Lipid Nanoparticles Leads to a More Powerful Immune Response Against SARS-CoV-2., PMID:40401447
Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice., PMID:40360777
Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity., PMID:40359129
Mimicking immune complexes for efficient antibody responses., PMID:40356891
Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein., PMID:40338637
Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination., PMID:40311214
Exploring TLR agonists as adjuvants for COVID-19 oral vaccines., PMID:40184639
Virus-specific antibody responses in severe acute respiratory syndrome coronavirus 2-infected and vaccinated individuals., PMID:40157431
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster., PMID:40044048
Association of infection-induced antibody levels with risk of subsequent SARS-COV-2 reinfection among healthcare professionals, Rhode Island, 1 March 2020-17 February 2021., PMID:39998388
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection., PMID:39983329
Validation and clinical performance of a non-commercial ELISA for SARS-CoV-2 anti-RBD IgA antibodies., PMID:39894142
mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity., PMID:39887249
IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility., PMID:39828085
Evaluation of anti-SARS-CoV-2 RBD antibody response after booster dose of SpikoGen® in individuals with two previous doses of Sinopharm and its association with HLA-DR and -DQ alleles., PMID:39764935
A SARS-CoV-2 mucosal nanovaccine based on assembly of maltodextrin, STING agonist and polyethyleneimine., PMID:39756748
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy., PMID:39744626
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization., PMID:39737197
Unraveling the impact of SARS-CoV-2 mutations on immunity: insights from innate immune recognition to antibody and T cell responses., PMID:39720734
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia., PMID:39490114
Unravelling the role of secretory Immnuoglobulin-A in COVID-19: a multicentre study in nursing homes during the first wave., PMID:39354348
An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA., PMID:39315545
Reassuring humoral and cellular immune responses to SARS-CoV-2 vaccination in participants with systemic sclerosis., PMID:39305938
The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment., PMID:39295862
Monitoring SARS-CoV-2 IgA, IgM and IgG antibodies in dried blood and saliva samples using antibody proximity extension assays (AbPEA)., PMID:39289450
Post-Hoc Analysis of Potential Correlates of Protection of a Recombinant SARS-CoV-2 Spike Protein Extracellular Domain Vaccine Formulated with Advax-CpG55.2-Adjuvant., PMID:39273405
Early, Robust Mucosal Secretory Immunoglobulin A but not Immunoglobulin G Response to Severe Acute Respiratory Syndrome Coronavirus 2 Spike in Oral Fluid Is Associated With Faster Viral Clearance and Coronavirus Disease 2019 Symptom Resolution., PMID:39269503
Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection., PMID:39248629
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters., PMID:39230305
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates., PMID:39227514
Salivary immune responses after COVID-19 vaccination., PMID:39226256
Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV-2., PMID:39196071
The Healthcare Study Examines the Humoral Anti-S1 Antibody Response Following mRNA Vaccination, Comparing Individuals with and without Prior SARS-CoV-2 Infection., PMID:39146978
Engineering receptor-binding domain and heptad repeat domains towards the development of multi-epitopes oral vaccines against SARS-CoV-2 variants., PMID:39146295
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles., PMID:39074077
Factors Influencing Breast Milk Antibody Titers during the Coronavirus Disease 2019 Pandemic: An Observational Study., PMID:39064762
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies., PMID:39039046
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays., PMID:38976733
Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective., PMID:38961063
Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals., PMID:38932145
Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice., PMID:38874361
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy., PMID:38867615
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice., PMID:38848648
Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice., PMID:38835757
Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection., PMID:38830902
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort., PMID:38779677
Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities., PMID:38779671
Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters., PMID:38675901
For research use only. Not for human or drug use.
